Cochlear and Vestibular Cell-Specific Promoters for Off-Target Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for hearing-related diseases lack specific promoters that can target and regulate gene expression in cochlear and vestibular hair cells, leading to unintended expression in non-target cells and potential side effects, and viral delivery methods risk infecting brain tissues.
Innovation Solution
Development of cochlear and vestibular cell-specific promoters, such as STRC, Slc26a5, otof, Sox10, Ngfr 1, Ngfr 2, and Dnah5, which are loaded into adeno-associated viral vectors to specifically express genes in target cells, reducing off-target expression and improving safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If constitutive promoters (CAG or CMV) are used for gene therapy, then exogenous genes can be expressed in cells, but expression occurs in non-target cells causing side effects and reducing safety
Solution Approach 1:
The patent applies local quality by developing cell-type-specific promoters (STRC for hair cells, Slc26a5 for outer hair cells, otof for inner hair cells, Sox10 for supporting cells, Ngfr1/Ngfr2 for spiral ganglion neurons, Dnah5 for vestibular hair cells) that enable selective gene expression in specific cochlear and vestibular cell types. This ensures therapeutic genes are expressed only in target cells, eliminating off-target expression and improving safety while maintaining therapeutic efficacy.
2Ease of manufacture
If viral injection is used to deliver genes through round window, then gene delivery is achieved, but viruses enter brain tissue through cerebrospinal fluid causing infection of brain cells
Solution Approach 1:
The patent uses cell-type-specific promoters to restrict viral gene expression to specific cochlear and vestibular cell types. Even when viruses are delivered via round window injection and enter brain tissue through cerebrospinal fluid, the specific promoters prevent expression of therapeutic genes in brain cells, thereby eliminating the harmful effect of brain infection while maintaining efficient gene delivery to target cells.
3Measurement precision
If transgenic animals are used for functional analysis, then specific cell type analysis is possible, but long reproduction cycles and high maintenance costs prevent flexible manipulation
Solution Approach 1:
The patent replaces the biological transgenic animal system with a molecular biology approach using cell-type-specific promoters combined with viral vector delivery. This substitution eliminates the need for long animal reproduction cycles and expensive maintenance while enabling precise functional analysis of specific cell types through controlled gene expression in cochlear and vestibular cells.
Solution Approach 2:
The patent changes the fundamental parameter of gene delivery from organism-level (transgenic animals) to cell-level (specific promoters with viral vectors). This parameter change allows immediate application without waiting for reproduction cycles, significantly reducing time loss while maintaining the ability to analyze specific cell types functionally.
Data Source
AI summary
A cochlear and/or vestibular cell-specific promoter and use thereof, and specifically relates to specific promoters STRC, Slc26a5, otof, Sox10, Ngfr 1, Ngfr 2, Dnah5 and use thereof in cochlear and/or vestibular cells. The nucleotide sequences of the specific promoters are shown as SEQ ID Nos: 1, 6, 11, 16, 21, 26, 31, respectively. A recombinant vector comprising the specific promoters. Based on the fact that the promoters are characterized by specific expression in the cochlea and/or vestibule, the use of the tissue-specific promoters, an amplification primer, the recombinant vector or a pharmaceutical composition in gene therapies, construction of related animal models, pathogenesis-related studies, and the like for hearing-related diseases is provided.